JPWO2019145475A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019145475A5 JPWO2019145475A5 JP2020560590A JP2020560590A JPWO2019145475A5 JP WO2019145475 A5 JPWO2019145475 A5 JP WO2019145475A5 JP 2020560590 A JP2020560590 A JP 2020560590A JP 2020560590 A JP2020560590 A JP 2020560590A JP WO2019145475 A5 JPWO2019145475 A5 JP WO2019145475A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- polymersome
- antigen
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 208
- 229920000575 polymersome Polymers 0.000 claims description 161
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 107
- 239000000427 antigen Substances 0.000 claims description 100
- 102000036639 antigens Human genes 0.000 claims description 98
- 108091007433 antigens Proteins 0.000 claims description 98
- 229920001184 polypeptide Polymers 0.000 claims description 98
- 206010022000 influenza Diseases 0.000 claims description 75
- 101710154606 Hemagglutinin Proteins 0.000 claims description 55
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 55
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 55
- 101710176177 Protein A56 Proteins 0.000 claims description 55
- 239000000185 hemagglutinin Substances 0.000 claims description 55
- 108010058846 Ovalbumin Proteins 0.000 claims description 53
- 229940092253 ovalbumin Drugs 0.000 claims description 53
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 47
- 230000028993 immune response Effects 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 42
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 41
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 40
- 229940096437 Protein S Drugs 0.000 claims description 40
- 101710198474 Spike protein Proteins 0.000 claims description 40
- 229960005486 vaccine Drugs 0.000 claims description 39
- 229920000642 polymer Polymers 0.000 claims description 38
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 35
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 claims description 32
- 230000004044 response Effects 0.000 claims description 29
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 27
- 108010088751 Albumins Proteins 0.000 claims description 23
- 102000009027 Albumins Human genes 0.000 claims description 23
- 102000002322 Egg Proteins Human genes 0.000 claims description 23
- 238000000338 in vitro Methods 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 230000002163 immunogen Effects 0.000 claims description 17
- 208000035473 Communicable disease Diseases 0.000 claims description 16
- 229920001400 block copolymer Polymers 0.000 claims description 15
- 210000004408 hybridoma Anatomy 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 15
- 229920001577 copolymer Polymers 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 13
- 230000000890 antigenic effect Effects 0.000 claims description 12
- 210000001163 endosome Anatomy 0.000 claims description 12
- 238000009566 cancer vaccine Methods 0.000 claims description 10
- 229940022399 cancer vaccine Drugs 0.000 claims description 10
- 229920000359 diblock copolymer Polymers 0.000 claims description 10
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000003308 immunostimulating effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 201000010740 swine influenza Diseases 0.000 claims description 8
- 206010012735 Diarrhoea Diseases 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 7
- 241000271566 Aves Species 0.000 claims description 6
- 108010052285 Membrane Proteins Proteins 0.000 claims description 6
- 102000018697 Membrane Proteins Human genes 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 230000005847 immunogenicity Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 241000282898 Sus scrofa Species 0.000 claims description 5
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 5
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 229960001438 immunostimulant agent Drugs 0.000 claims description 5
- 239000003022 immunostimulating agent Substances 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 230000001590 oxidative effect Effects 0.000 claims description 5
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 108010000912 Egg Proteins Proteins 0.000 claims description 4
- 230000024932 T cell mediated immunity Effects 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 235000014103 egg white Nutrition 0.000 claims description 4
- 210000000969 egg white Anatomy 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 claims description 4
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000028996 humoral immune response Effects 0.000 claims description 3
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 229920000428 triblock copolymer Polymers 0.000 claims description 3
- 206010011732 Cyst Diseases 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 241000283984 Rodentia Species 0.000 claims description 2
- 208000031513 cyst Diseases 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 210000000003 hoof Anatomy 0.000 claims description 2
- 229960003971 influenza vaccine Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 34
- 238000001727 in vivo Methods 0.000 description 19
- -1 alkylene sulfide Chemical compound 0.000 description 16
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 9
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 8
- 229920000471 Poly(ethylene oxide)-block-polylactide Polymers 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 5
- 229920001610 polycaprolactone Polymers 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 229920005615 natural polymer Polymers 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 3
- 229920006254 polymer film Polymers 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- OANLWIQYRRVBPY-UHFFFAOYSA-N 2-thiophen-3-ylethanamine Chemical compound NCCC=1C=CSC=1 OANLWIQYRRVBPY-UHFFFAOYSA-N 0.000 description 2
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 241000272814 Anser sp. Species 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- LAQFLZHBVPULPL-UHFFFAOYSA-N methyl(phenyl)silicon Chemical compound C[Si]C1=CC=CC=C1 LAQFLZHBVPULPL-UHFFFAOYSA-N 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 125000006353 oxyethylene group Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 2
- 229940065514 poly(lactide) Drugs 0.000 description 2
- 229920003216 poly(methylphenylsiloxane) Polymers 0.000 description 2
- 229920000917 poly(propylene sulfide) Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- DVOHUMWWYKJUIL-CHMOTEOASA-N (2s)-2-amino-3-[[(2r)-3-hexadecanoyloxy-2-[(z)-octadec-9-enoxy]propoxy]-hydroxyphosphoryl]oxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OCCCCCCCC\C=C/CCCCCCCC DVOHUMWWYKJUIL-CHMOTEOASA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 229920001963 Synthetic biodegradable polymer Polymers 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024134738A JP2024160341A (ja) | 2018-01-25 | 2024-08-13 | 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18153348 | 2018-01-25 | ||
| EP18153348.0 | 2018-01-25 | ||
| PCT/EP2019/051853 WO2019145475A2 (en) | 2018-01-25 | 2019-01-25 | Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024134738A Division JP2024160341A (ja) | 2018-01-25 | 2024-08-13 | 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021512142A JP2021512142A (ja) | 2021-05-13 |
| JP2021512142A5 JP2021512142A5 (https=) | 2022-02-01 |
| JPWO2019145475A5 true JPWO2019145475A5 (https=) | 2022-02-01 |
| JP7542257B2 JP7542257B2 (ja) | 2024-08-30 |
Family
ID=61192649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560590A Active JP7542257B2 (ja) | 2018-01-25 | 2019-01-25 | 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法 |
| JP2024134738A Pending JP2024160341A (ja) | 2018-01-25 | 2024-08-13 | 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024134738A Pending JP2024160341A (ja) | 2018-01-25 | 2024-08-13 | 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12239736B2 (https=) |
| EP (1) | EP3743101A2 (https=) |
| JP (2) | JP7542257B2 (https=) |
| CN (1) | CN111954541A (https=) |
| BR (1) | BR112020013405A2 (https=) |
| WO (1) | WO2019145475A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201704135QA (en) * | 2012-11-19 | 2017-06-29 | Agency Science Tech & Res | Method For Eliciting An Immune Response To An Immunogen |
| CN114502191B (zh) * | 2019-08-01 | 2026-04-03 | Acm生物实验室私人有限公司 | 通过施用具有关联的抗原的聚合物囊泡群和具有关联的佐剂的聚合物囊泡群来引发免疫应答的方法以及包含这两种聚合物囊泡群的组合物 |
| US11642407B2 (en) | 2020-02-28 | 2023-05-09 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
| US20230256082A1 (en) * | 2020-04-24 | 2023-08-17 | Acm Biolabs Pte Ltd | Vaccine against human-pathogenic coronaviruses |
| JP2024500360A (ja) * | 2020-12-11 | 2024-01-09 | エイシーエム バイオラブズ プライベート リミテッド | 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法 |
| CA3204785A1 (en) * | 2021-02-02 | 2022-08-11 | Madhavan Nallani | Sole use of polymersome associated adjuvant for stimulating an immune response |
| WO2022218957A1 (en) * | 2021-04-12 | 2022-10-20 | Acm Biolabs Pte Ltd | Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof |
| CN113416788B (zh) * | 2021-07-14 | 2022-04-29 | 兰州大学 | 一种与湖羊睾丸性状相关的adpgk基因分子标记及其应用 |
| WO2023183287A2 (en) * | 2022-03-21 | 2023-09-28 | The University Of North Carolina At Chapel Hill | Composite bioactive compositions and applications thereof |
| WO2024081641A2 (en) * | 2022-10-10 | 2024-04-18 | Northwestern University | Methods for preparing protein-conjugated nanocarriers |
| CN117045809B (zh) * | 2023-09-27 | 2025-08-29 | 国家纳米科学中心 | 异种哺乳动物细胞来源的囊泡在制备疫苗载体中的应用 |
| CN120860194A (zh) * | 2025-07-15 | 2025-10-31 | 中国人民解放军总医院第一医学中心 | 一种流感病毒纳米疫苗及其制备方法与应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US569825A (en) | 1896-10-20 | John h | ||
| US633425A (en) | 1899-01-26 | 1899-09-19 | Louis Henry Clyborne | Wire-tightener. |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| FR2766205B1 (fr) * | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
| DE602004025711D1 (de) | 2003-08-21 | 2010-04-08 | Lipotek Pty Ltd | In vivo targeting von dendritischen zellen |
| WO2008060557A2 (en) | 2006-11-14 | 2008-05-22 | The Trustees Of The University Of Pennsylvania | Efficient nuclear delivery of antisense oligonucleotides |
| US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
| EP2601262A4 (en) * | 2010-08-05 | 2014-01-22 | Agency Science Tech & Res | VESIGN STRUCTURE WITH SEVERAL CHAMBERS AND METHOD FOR THEIR EDUCATION |
| CA2866170A1 (en) | 2012-03-12 | 2013-09-19 | Advanced Bioadjuvants, Llc | Adjuvant and vaccine compositions |
| SG10201704135QA (en) | 2012-11-19 | 2017-06-29 | Agency Science Tech & Res | Method For Eliciting An Immune Response To An Immunogen |
| US10017545B2 (en) * | 2013-06-03 | 2018-07-10 | University Of Maryland, College Park | Compositions and vaccines comprising vesicles and methods of using the same |
| EP2898894A1 (en) | 2014-01-27 | 2015-07-29 | LTS LOHMANN Therapie-Systeme AG | Nano-in-micro particles for intradermal delivery |
| WO2016055611A1 (en) | 2014-10-09 | 2016-04-14 | Universität Basel | Self-assembled nanostructures and methods of use thereof |
| US9636397B2 (en) | 2015-03-24 | 2017-05-02 | VaxLiant, LLC | Adjuvant compositions and related methods |
| MX2018010586A (es) * | 2016-03-02 | 2019-03-28 | Univ Texas | Nanovacuna de activacion de "sting" para inmunoterapia. |
-
2019
- 2019-01-25 EP EP19704741.8A patent/EP3743101A2/en active Pending
- 2019-01-25 CN CN201980021354.5A patent/CN111954541A/zh active Pending
- 2019-01-25 BR BR112020013405-8A patent/BR112020013405A2/pt unknown
- 2019-01-25 WO PCT/EP2019/051853 patent/WO2019145475A2/en not_active Ceased
- 2019-01-25 US US16/964,931 patent/US12239736B2/en active Active
- 2019-01-25 JP JP2020560590A patent/JP7542257B2/ja active Active
-
2024
- 2024-08-13 JP JP2024134738A patent/JP2024160341A/ja active Pending
-
2025
- 2025-02-25 US US19/063,054 patent/US20250186346A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512142A5 (https=) | ||
| CN108743939B (zh) | 共载抗原、mpla与imq的阳离子磷脂-聚合物杂化纳米粒疫苗佐剂及制备方法与应用 | |
| Sahdev et al. | Biomaterials for Nanoparticle Vaccine Delivery Systems: Sahdev, Ochyl and Moon | |
| Shahiwala et al. | Nanocarriers for systemic and mucosal vaccine delivery | |
| JP6625587B2 (ja) | Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用 | |
| US8017154B2 (en) | Polyamino acid for use as adjuvant | |
| JP2021020967A (ja) | 免疫原性化合物 | |
| CN104288758B (zh) | 聚乙二醇化磷脂为载体的胶束多肽疫苗 | |
| US11628208B2 (en) | System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins | |
| Beg et al. | Colloidal drug delivery systems in vaccine delivery | |
| Roopngam | Liposome and polymer-based nanomaterials for vaccine applications. | |
| JPWO2019145475A5 (https=) | ||
| Goyal et al. | Nanotechnological approaches for genetic immunization | |
| KR20030061838A (ko) | 면역원성이 불량한 항원의 면역원성을 향상시키는 약제조성물 | |
| Lee et al. | Biodegradable cationic polycarbonates as vaccine adjuvants | |
| KR20140099828A (ko) | 점막 투여용 백신 조성물 | |
| KR101507119B1 (ko) | 점막 점착성 폴리감마글루탐산 나노마이셀 및 이를 이용한 약물 전달체 | |
| CN105194663A (zh) | 聚乙二醇化磷脂为载体的胶束多肽疫苗 | |
| Singh et al. | Applications of nanotechnology in vaccine delivery | |
| US20040126421A1 (en) | Liposomal system and method of using same | |
| Arora et al. | Oral mucosal immunization: Recent advancement and future prospects | |
| Patel et al. | Cationic nanoparticles for delivery of CpG oligodeoxynucleotide and ovalbumin: In vitro and in vivo assessment | |
| Orosco et al. | Next-generation subunit vaccine delivery systems: Design, applications, and prospects | |
| Brown et al. | Nucleic Acids as Adjuvants | |
| 이혜선 | Development of adjuvants using cytokine and polymeric particles for efficient mucosal immunization |